New Drug Approvals
MAY 9, 2025
1] [8] Pharmacokinetics Elacestrant has an oral bioavailability of approximately 10%. [1] 1] [4] It is taken by mouth. [1] 1] [4] Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors , which are the biological targets of endogenous estrogens like estradiol. [1] 3] [7] PATENTS Cruskie MP, et al.
New Drug Approvals
JULY 25, 2025
12] History In phase I clinical trials of adult volunteers, vamorolone was shown to be safe and well tolerated, with blood biomarker data suggesting possible loss of safety concerns of the corticosteroid class. [13] “Drug Trials Snapshots: Agamree” U.S. Food and Drug Administration (FDA). 2 (1): e201800186.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
New Drug Approvals
JULY 18, 2025
Additionally, the studies tended to use a smaller number of participants than other major COVID-19 drug trials. [12] However, some studies produced inconsistent results in terms of symptom improvement and severe illness prevention. 7] No generics are available. . 98 : 379–386. doi : 10.1016/j.jpba.2014.06.019. 2014.06.019.
Drug Target Review
OCTOBER 3, 2024
Overcoming traditional antibody generation limitations with recombinant technologies Antibodies remain essential tools in this ever-changing field for preclinical bioanalysis and drug monitoring through ligand-binding assays (LBAs). FDA no longer needs to require animal tests before human drug trials [Internet]. www.science.org.
Drug Target Review
SEPTEMBER 19, 2023
Pharmaceutical companies adapted the usage of organoids derived from specific patient derived tumours in cancer drug screening process for testing drug toxicities and efficacy. Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity. Nature Cancer.
Alta Sciences
JULY 31, 2024
Why Diversity in Clinical Trials Matters A wide variety of factors, from age or biological sex to environmental conditions and lifestyle choices (e.g., substance abuse, sexual activity), can influence the risk and likelihood of developing a disease or other long-term health issues—as well as the way an individual responds to treatment.
New Drug Approvals
MAY 14, 2025
7] This pharmacokinetic property has supported its investigation for the treatment of deep-seated Candida infections, including osteomyelitis. [8] 2] It is an echinocandin antifungal [1] [4] that acts as a fungal -glucan synthase inhibitor. [5] 2] [3] CAS No. 2] The applicant for this medicinal product is Mundipharma GmbH. [2] 23 March 2023.
Expert insights. Personalized for you.
Let's personalize your content